Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Sun Pharma Share Price Live Updates: Sun Pharma's Trading Update
Small-caps, PSUs and pharma remain Gautam Shah's top market themes for 2026
Gautam Shah, Founder of Goldilocks Global Research, sees the Nifty remaining range-bound between 23,150 and 24,000, while forecasting the small-cap index could rise to 20,000. Shah also believes Indian IT stocks are nearing a bottom and that PSU stocks could deliver 25-30% returns over the next 12-18 months.
Sun Pharma Share Price Live Updates: Sun Pharma's Recent Trading Volume
Sun Pharmaceutical Industries Ltd drops for fifth straight session
Sun Pharmaceutical Industries Ltd is quoting at Rs 1774.1, down 0.81% on the day as on 13:19 IST on the NSE. The stock jumped 5.41% in last one year as compared to a 5.65% slide in NIFTY and a 11.71% spurt in the Nifty Pharma index.
Nifty trades below 23,400 level; European mrkt decline
Consumer durables, realty and pharma shares advanced while metal, private bank and IT shares declined.
Sun Pharma Share Price Live Updates: Sun Pharma Sees Price Increase Exceeding 5%
Novelix Pharma inks pact with German Firm to boost Astaxanthin output
Novelix Pharmaceuticals entered into an agreement with GMBU e.V., Halle (Saale), Germany, to scale up the production of Astaxanthin at the company's research facilities in Hyderabad.
Sun Pharma Share Price Live Updates: Sun Pharma's beta showcases its market positioning
BofA sees domestic growth, Semaglutide opportunity driving pharma in FY27
Neha Manpuria, Senior Analyst - Pharma, Healthcare at BofA Global Research, says semaglutide launches could emerge as a key growth driver for Indian pharma companies in FY27.
Market trade near day's high; European mrkt advance
IT, consumer durables and auto shares advanced while pharma, media and oil & gas shares declined.
Sun Pharma Share Price Live Updates: Sun Pharma's Volume Analysis
Wockhardt’s new drug, India’s second to get US nod, now eyes commercial success
The nod for Zaynich—an antibiotic for treatment of complicated UTI—vindicates chairman and founder Habil Khorakiwala’s bet on antibiotic discovery and development, even as Big Pharma companies in developed economies stopped such research in favour of more lucrative drugs.